eli lilly tirzepatide patient assistance program Financial Options Zepbound price cut: Eli Lilly

What the Clinical Data Actually Shows The most definitive comparison comes from the SURMOUNT-5 trial, a direct head-to-head study published in the New England Journal of Medicine comparing tirzepatide 10 mg and 15 mg against semaglutide 2.4 mg in adults with obesity but without diabetes

Take weekly check-ins seriously This cannot be overstated

When you can show documented patterns (like nausea always peaking 48 hours after an injection, or energy drops connecting with low protein intake for three days), your provider can make informed adjustments, instead of guessing based on unclear descriptions of how you feel

What this means for pricing Reduced supply with continued demand means prices have increased for whatever compounded tirzepatide remains available

Brand products undergo extensive FDA review and quality control

In the landmark SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of their body weight over 72 weeks, but that loss accumulated steadily over time rather than all at once